EHMT2 and acute lymphoblastic leukemia: The results strongly suggested that in T-ALL, G9a suppression inhibits Glycogen Synthase Kinase 3 (GSK-3), demonstrating an effective epigenetic control on glycolytic pathways to deplete the metabolic requirement of T-ALL cells [102].